Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 09 04:00PM ET
0.6261
Dollar change
-0.0320
Percentage change
-4.86
%
Index- P/E- EPS (ttm)-0.21 Insider Own11.49% Shs Outstand255.70M Perf Week-13.43%
Market Cap160.21M Forward P/E- EPS next Y-0.08 Insider Trans-0.08% Shs Float226.47M Perf Month-19.41%
Income-45.01M PEG- EPS next Q-0.03 Inst Own47.94% Short Float3.05% Perf Quarter-42.03%
Sales175.60M P/S0.91 EPS this Y70.37% Inst Trans-3.96% Short Ratio4.46 Perf Half Y-39.80%
Book/sh0.31 P/B2.00 EPS next Y-212.49% ROA-14.66% Short Interest6.91M Perf Year9.86%
Cash/sh0.73 P/C0.86 EPS next 5Y- ROE-53.54% 52W Range0.43 - 2.05 Perf YTD-21.05%
Dividend Est.- P/FCF- EPS past 5Y10.30% ROI-29.94% 52W High-69.46% Beta2.18
Dividend TTM- Quick Ratio3.82 Sales past 5Y134.88% Gross Margin93.57% 52W Low45.60% ATR (14)0.06
Dividend Ex-Date- Current Ratio3.85 EPS Y/Y TTM57.01% Oper. Margin-32.90% RSI (14)36.80 Volatility8.69% 9.91%
Employees449 Debt/Eq0.93 Sales Y/Y TTM145.37% Profit Margin-25.63% Recom1.89 Target Price2.71
Option/ShortYes / Yes LT Debt/Eq0.88 EPS Q/Q65.25% Payout- Rel Volume1.31 Prev Close0.66
Sales Surprise115.68% EPS Surprise-5.26% Sales Q/Q467.86% EarningsNov 14 BMO Avg Volume1.55M Price0.63
SMA20-8.61% SMA50-19.10% SMA200-42.14% Trades Volume2,033,995 Change-4.86%
Date Action Analyst Rating Change Price Target Change
Jul-30-24Initiated H.C. Wainwright Buy $4
May-30-24Initiated Scotiabank Sector Outperform $3.15
Mar-24-23Initiated Bryan Garnier Buy $3.60
Jan-03-23Upgrade Guggenheim Neutral → Buy $5
Nov-09-22Upgrade Mizuho Neutral → Buy $9
May-28-21Initiated Barclays Underweight $4
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
Dec-02-24 04:00PM
Nov-15-24 05:00AM
Nov-14-24 11:55AM
02:15AM
Nov-13-24 04:05PM
09:00AM Loading…
09:00AM
Nov-05-24 09:19AM
Oct-31-24 05:20PM
Sep-20-24 08:35AM
Sep-16-24 12:07PM
Aug-28-24 08:00AM
Aug-12-24 07:00AM
Aug-09-24 07:13AM
Aug-05-24 08:00AM
Aug-02-24 11:53AM
08:46AM Loading…
08:46AM
06:54AM
Aug-01-24 08:20PM
Jul-24-24 11:13PM
Jul-03-24 11:11AM
06:00AM
Jun-03-24 12:00PM
May-31-24 07:39AM
May-30-24 04:01PM
04:01PM
May-17-24 06:49AM
May-16-24 08:18AM
May-15-24 12:53PM
11:07AM
07:30AM
07:00AM Loading…
07:00AM
May-01-24 12:00PM
Apr-23-24 07:45AM
Apr-15-24 02:12PM
Apr-12-24 08:00AM
05:37AM
Mar-27-24 07:30PM
Mar-07-24 01:42PM
08:24AM
Mar-06-24 12:52PM
07:00AM
Feb-27-24 08:00AM
Feb-21-24 04:00PM
Feb-16-24 03:57AM
Feb-13-24 06:15PM
Jan-31-24 04:44PM
Jan-30-24 01:02PM
Jan-16-24 11:17AM
Jan-04-24 07:37AM
Dec-06-23 07:00AM
Nov-30-23 10:52AM
Nov-29-23 08:00AM
Nov-13-23 09:35AM
08:35AM
Nov-08-23 07:30AM
07:05AM
Nov-07-23 06:15PM
Oct-31-23 08:00AM
08:00AM
Oct-27-23 06:15PM
Oct-25-23 08:06AM
Oct-23-23 04:15AM
Sep-11-23 08:00AM
Aug-09-23 07:29AM
Aug-03-23 01:24PM
Jul-28-23 12:30PM
Jul-20-23 07:28AM
Jul-16-23 08:18PM
Jun-29-23 09:18AM
Jun-26-23 11:23AM
11:15AM
Jun-23-23 09:15AM
Jun-22-23 09:40AM
Jun-19-23 10:18AM
Jun-16-23 08:39AM
Jun-15-23 09:43AM
08:18AM
Jun-13-23 10:14AM
Jun-12-23 10:00AM
09:48AM
Jun-09-23 10:52AM
Jun-06-23 06:50AM
Jun-05-23 11:40AM
10:22AM
Jun-01-23 03:29PM
May-30-23 09:35AM
May-25-23 05:00PM
May-12-23 07:29AM
May-09-23 06:43AM
May-05-23 05:00AM
Apr-28-23 12:00PM
Apr-18-23 11:49AM
Apr-12-23 10:42AM
Apr-11-23 12:13PM
08:00AM
Mar-08-23 07:14AM
05:23AM
Mar-06-23 01:08PM
06:30AM
06:00AM
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Piccina CintiaChief Commercial OfficerJun 18 '24Sale0.9324,53122,81438,293Jun 18 05:00 PM
Rawcliffe AdrianChief Executive OfficerJan 17 '24Sale0.6730,08020,24444,848Jan 17 05:31 PM
Rawcliffe AdrianChief Executive OfficerJan 16 '24Sale0.799,3047,35014,104Jan 17 05:31 PM
Norry ElliotChief Medical OfficerJan 17 '24Sale0.6718,27612,3007,785Jan 17 05:31 PM
Norry ElliotChief Medical OfficerJan 16 '24Sale0.792,2871,8073,363Jan 17 05:31 PM
Lunger JohnChief Patient Supply OfficerJan 17 '24Sale0.6718,11412,1917,785Jan 17 05:30 PM
Lunger JohnChief Patient Supply OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Bertrand William C JRChief Operating OfficerJan 17 '24Sale0.6718,90812,7257,785Jan 17 05:30 PM
Bertrand William C JRChief Operating OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Norry ElliotChief Medical OfficerJan 12 '24Sale0.857,7996,66111,841Jan 12 05:00 PM
Norry ElliotChief Medical OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerJan 12 '24Sale0.8517,25714,73926,388Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerJan 11 '24Sale0.8411,9459,99418,395Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM